Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

NCT03390673 is registered in ClinicalTrials.gov with Prestige Biopharma Limited as lead sponsor.

NCT NCT03390673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03390673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
Lead sponsor
Prestige Biopharma Limited
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2018
Completion date
March 13, 2019
Enrollment
119 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers